Leerink Partners Initiates Coverage of Senti Biosciences with Outperform Recommendation, Analyst Price Forecast Suggests 632.60% Upside.

Leerink Partners initiates coverage of Senti Biosciences (SNTI) with an Outperform recommendation. The average one-year price target is $13.26/share, representing a 632.60% increase from its latest closing price. Projected annual revenue is 5MM, with a non-GAAP EPS of -1.57. There are 28 funds reporting positions in SNTI, with an average portfolio weight of 0.01%. Key shareholders include NEA Management Company, Nantahala Capital Management, and Geode Capital Management.